Association of Polymorphisms in Inflammation Genes With the Prognosis of Advanced Non-Small Cell Lung Cancer Patients Receiving Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Background: Inflammation is not only involved in the development and progression of cancer but also affects the response to therapy. The aim of this study was to investigate the association of single nucleotide polymorphisms (SNPs) in inflammation genes with the prognosis of advanced non-small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).

Methods: Forty-seven SNPs were genotyped in 318 advanced NSCLC patients receiving EGFR-TKIs. Of 318 patients, 182 (57.2%) patients died during follow-up period. We assessed the association of SNPs with the progression-free survival (PFS) and overall survival (OS) as well as calculated the weighted genetic risk score (GRS). We also explored the expression levels and prognostic values of inflammation genes in lung adenocarcinoma (LUAD) in Gene Expression Profiling Interactive Analysis (GEPIA) and using UCSC Xena, respectively. The relationship between the expression levels of IL15, IL17RA, AGER, MIF, and TNFRSF1A and EGFR mutation status was analyzed using UCSC Xena.

Results: In single variant analyses, 3 SNPs (rs10519613, rs4819554, and rs4149570) were significantly associated with worse PFS. Five SNPs (rs10519613, rs4819554, rs2070600, rs755622, and rs4149570) were significantly with worse OS. In addition, high and intermediate GRSs (based on rs10519613, rs4819554, and rs4149570) were associated with worse PFS than those with low GRS. For OS, patients with high GRSs (based on rs10519613, rs4819554, rs2070600, rs755622, and rs4149570) had shorter survival time than those with low GRS. Furthermore, IL15, IL17RA, AGER, MIF, and TNFRSF1A were dysregulated in LUAD. There was difference in the expression level of TNFRSF1A between EGFR wildtype and EGFR-mutant LUAD. Both low AGER expression and high TNFRSF1A expression were significantly associated with worse PFS in LUAD. In addition, low IL17RA and AGER expression, high MIF and TNFRSF1A expression were significantly associated with worse OS in LUAD.

Conclusion: SNPs in inflammation genes could serve as prognostic biomarkers for NSCLC patients treated with EGFR-TKIs.

Introduction

Lung cancer is the second most common cancer and the leading cause of cancer death worldwide, with 2.2 million new cases and 1.8 million deaths annually, accounting for almost 1 in 10 (11.4%) cases and 1 in 5 (18.0%) cancer deaths globally (1). China is a country with a high incidence of lung cancer, ranking the first for both incidence and mortality (2). The incidence and mortality rates of lung cancer remain high for many years. Whether high incidence or high mortality rates of lung cancer undoubtedly make it a major problem of public health in China. At present, most of metastatic lung cancer still cannot be cured. Although the combined application of surgery, chemotherapy, radiotherapy, and targeted therapy has significantly improved the survival rate of lung cancer patients, the prognosis of lung cancer is still poor (3). For example, the 5-year overall survival rate of TNM stage IA lung cancer is about 85%, while that of TNM stage IV lung cancer is only 6% (4, 5). The most effective treatment strategy could be selected by analyzing molecular markers to guide individualized treatment, which can maximize the efficacy and minimize toxicity, and achieve the goal of improving the survival rate and quality of life of patients.

Epidermal growth factor receptor (EGFR) mutations are present in about ~50.2% of non-small cell lung cancer (NSCLC) (6, 7). Tyrosine kinase inhibitors (TKIs) targeting EGFR have made great progress in the treatment of NSCLC patients harboring activating EGFR mutations. TKIs have obviously increased the disease-specific survival for NSCLC patients (8, 9). To date, first-, second-, and third-generation EGFR-TKIs are approved as the standard first-line treatments for EGFR-mutated patients (10, 11). However, the objective response rate of EGFR-TKIs is approximately ~80%, indicating that at least 20% of patients may not benefit from EGFR-TKI therapy (12, 13). Acquired resistance inevitably develops in most patients receiving EGFR-TKIs within 1 to 2 years of therapy (12, 14). Patients who failed EGFR-TKIs have little choice other than cytotoxic chemotherapy due to very limited kinds of targeted drugs. Therefore, it is necessary to develop therapeutic strategies or discover drugs that delay the emergence of EGFR-TKI resistance or reverse this effect and to identify more novel predictive biomarkers that can accurately predict the efficacy of EGFR-TKIs.

Inflammation is not only involved in the occurrence, progression, angiogenesis, invasion and metastasis of cancer (15, 16), but is also closely related to 15% of cancer deaths (17). The lung is the most common site of inflammation due to environmental exposure. Pulmonary inflammatory diseases such as chronic obstructive pulmonary disease are associated with increased risk and poor prognosis of lung cancer (18, 19). Many studies have shown that inflammatory molecules and their effectors are independent risk factors for disease progression and survival of advanced lung cancer (20–24). Circulating inflammatory markers such as C-reactive protein (CRP), cytokines, neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-monocyte ratio (LMR) are associated with the prognosis of NSCLC patients receiving EGFR-TKIs (20, 23, 25–28). A recent study by Yamaoka et al. (29) found that high level of tumor necrosis factor (TNF) may enhance the development of EGFR TKI-induced pneumonitis, which was responsible for more than half of the toxic deaths following the administration of EGFR-TKIs (30). The clinical outcomes of NSCLC patients receiving EGFR-TKIs appear to be influenced by the degree of systemic inflammation at diagnosis. Single nucleotide polymorphisms (SNPs) may affect the expression and function of inflammation genes. Therefore, SNPs in inflammation genes may be associated with clinical outcome of NSCLC patients treated with EGFR-TKIs. The aim of this study was to investigate the effect of SNPs inflammation genes on the prognosis of patients with advanced NSCLC patients treated with EGFR TKIs.

Materials and Methods

Patients

A total of 318 advanced NSCLC patients with EGFR mutations were recruited at Taizhou Central Hospital between 2015 and 2017. All patients must meet the following inclusion criteria: 1) histologically or cytologically confirmed TNM stages IIIB and IV NSCLC; 2) aged 20 and older; 3) activating EGFR mutations; 4) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2; 5) no history of systemic anticancer therapy including chemotherapy and radiotherapy. Patients were initially treated with first-generation EGFR-TKIs orally daily until either intolerable toxicity or disease progression occurred. In addition, if patients developed severe adverse effects, EGFR-TKIs doses were appropriately reduced. The study was approved by the Ethics Committees of Taizhou Central Hospital and all patients provided signed informed consent.

Genotyping

Fourth-seven inflammation genes were selected based on a literature review. For each candidate gene, SNPs associated with human disease susceptibility, prognosis, and treatment outcomes were searched in PubMed. For the coding SNPs of candidate genes not reported in the literature, those with allele frequency greater than 0.05 in Chinese population were selected. Furthermore, only SNPs with a minimum allele frequency (MAF) greater than 0.05 were selected for genotyping in order to improve the statistical efficiency. Finally, a total of 47 SNPs were selected from 47 inflammation genes (Table S1). Genomic DNA was extracted from whole blood using the TaKaRa MiniBEST Whole Blood Genomic DNA Extraction Kit (TakaRa, Dalian, China) according to the manufacturer’s instructions. All SNPs were genotyped using a PCR-ligation detection reaction (LDR) method as previously described (3).

Gene Expression Analysis

Gene Expression Profiling Interactive Analysis (GEPIA) was used to analyze the expression levels of IL15, IL17RA, AGER, MIF, and TNFRSF1A in 483 lung adenocarcinoma (LUAD) and 387 normal tissues from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) portal (31). The relationship between the expression levels of IL15, IL17RA, AGER, MIF, and TNFRSF1A and EGFR mutation status was analyzed using UCSC Xena (32). The progression-free survival (PFS) and overall survival (OS) were also analysis using UCSC Xena.

Statistical Analyses

Weighted genetic risk score (GRS) was constructed to evaluate the cumulative effect of SNPs on the prognosis of NSCLC patients. Only SNPs with P value less than 0.05 entered the GRS with a coding value of 0 for non-risk allele homozygotes, 1 for heterozygotes, and 2 for risk-allele homozygotes. For each subject, we generated a GRS according to the formula: $GRS={\Sigma }_{i=1}^{n}SN{P}_i\times {\beta }_i$. β_i was the HR of the SNPi, whereas SNPi represented its code value. All patients were divided into low (1st quintile), intermediate (2nd–3th quintile), and high (4th quintile) GRS groups. PFS and OS rates were calculated using the Kaplan–Meier method. The differences in PFS and OS rates across different genotypes were compared using the log-rank test. Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the evaluation of the association between SNPs and survival. A P value < 0.05 was considered statistically significant.

Results

Clinicopathologic Characteristics

Clinicopathologic characteristics of NSCLC patients were presented in Table 1. In brief, most of patients were female (66.7%). Mean age at diagnosis was 56.7 years. The median survival time was 22.0 months. A total of 182 (57.2%) patients died during follow-up period. TNM stage was significantly associated with both worse PFS (P = 0.020) and OS (P = 0.005). In addition, ECGO was week but significantly associated with worse OS (P = 0.047). There was no significant difference in PFS regarding to sex, age, ECGO, and smoking status (P > 0.05). There was also no significant difference in mortality rate regarding to sex, age, and smoking status (P > 0.05).

TABLE 1

Table 1 Characteristics of the study populations at the time of analysis.

Associations Between SNPs and Survival Outcomes

The individual association of each SNP with the prognosis of NSCLC patients was shown in Table 2. Among 47 SNPs, 3 SNPs (rs10519613, rs4819554, and rs4149570) were significantly associated with worse PFS of NSCLC patients (Figure 1). Multivariate Cox’s proportional hazards regression analysis showed that rs10519613 (adjusted HR = 1.209, 95% CI 1.028-1.422, P = 0.022), rs4819554 (adjusted HR = 1.373, 95% CI 1.151-1.637, P  <  0.001), and rs4149570 (adjusted HR = 1.342, 95% CI 1.134-1.587, P = 0.001) were independent prognostic factors for worse PFS of NSCLC patients (Table 2). Furthermore, 5 SNPs (rs10519613, rs4819554, rs2070600, rs755622, and rs4149570) were significantly with worse OS of NSCLC patients (Figure 2). Multivariate Cox’s proportional hazards regression analysis showed that rs10519613 (adjusted HR = 1.282, 95% CI 1.047-1.569, P = 0.016), rs4819554 (adjusted HR = 1.319, 95% CI 1.060-1.641, P = 0.013), rs2070600 (adjusted HR = 1.333, 95% CI 1.068-1.664, P = 0.011), rs755622 (adjusted HR = 1.345, 95% CI 1.057-1.713, P = 0.016), and rs4149570 (adjusted HR = 1.328, 95% CI 1.083-1.627, P = 0.006) were independent prognostic factors for worse OS of NSCLC patients.

TABLE 2

Table 2 Associations of SNPs of inflammation genes with PFS and OS of advanced lung adenocarcinoma patients treated with EGFR-TKIs.

FIGURE 1

Figure 1 Kaplan-Meier curves of PFS for advanced NSCLC patients treated with EGFR TKIs according to genotypes. (A), rs10519613. (B), rs4819554. (C), rs4149570.

FIGURE 2

Figure 2 Kaplan-Meier curves of OS for advanced NSCLC patients treated with EGFR TKIs according to genotypes. (A), rs10519613. (B), rs4819554. (C), rs4149570. (D), rs2070600. (E), rs755622.

Associations Between GRS and Survival Outcomes

Survival analysis according to GRS was shown in Table 3. Patients with high GRS (based on rs10519613, rs4819554, and rs4149570) had significantly shorter PFS (6.5 months) than those with intermediate (7.9 months) and low GRSs (11.6 months, P < 0.001) (Figure 3). Multivariate Cox’s proportional hazards regression analysis showed that intermediate (adjusted HR = 1.432, 95%CI 1.082-1.897, P = 0.012) and high GRSs (adjusted HR = 2.008, 95%CI 1.453-2.774, P < 0.001) were significantly associated with worse PFS of NSCLC patients. We further also evaluated the association of GRS (based on rs10519613, rs4819554, rs2070600, rs755622, and rs4149570) with OS. Patients with high GRS had significantly shorter OS (15.0 months) than those with intermediate (24.0 months) and low GRSs (31.0 months, P < 0.001). Multivariate Cox’s proportional hazards regression analysis showed that high GRSs (adjusted HR = 2.816, 95%CI 1.845-4.300, P < 0.001) were significantly associated with worse OS of NSCLC patients.

TABLE 3

Table 3 Associations of GRSs with PFS and OS of advanced lung adenocarcinoma patients treated with EGFR-TKIs.

FIGURE 3

Figure 3 Kaplan-Meier survival curves for advanced NSCLC patients treated with EGFR TKIs according to GRSs. (A), PFS. (B), OS.

Sex-Stratified Analysis

Previous studies have shown that female patients have higher frequency of EGFR mutation (33, 34), which suggested whether sex may influence the effect of SNPs on clinical outcome of NSCLC patients. We further conducted a sex-stratified analysis of the aforementioned statistically significant SNPs that were associated with the clinical outcome of NSCLC patients. Among female NSCLC patients, only high GRS was significantly associated with both PFS (adjusted HR = 1.629, 95%CI 1.105-2.400, P = 0.014) and OS (adjusted HR = 1.967, 95%CI 1.176-3.289, P = 0.010), and rs10519613 was weakly but significantly associated with worse OS (adjusted HR = 1.312, 95%CI 1.021-1.687, P = 0.034) (Table 4). Among male NSCLC patients, intermediate and high GRSs, rs4819554, and rs4149570 were significantly associated with both PFS and OS (P < 0.05). Furthermore, rs10519613 and rs755622 were significantly associated with worse PFS (adjusted HR = 1.392, 95%CI 1.034-1.874, P = 0.029) and OS (adjusted HR = 1.699, 95%CI 1.172-2.463, P = 0.005), respectively.

TABLE 4

Table 4 Associations of SNPs and GRS with OS and PFS of advanced lung adenocarcinoma patients treated with EGFR-TKI stratified by sex.

Associations Between the Expression of IL15, IL17RA, AGER, MIF, and TNFRSF1A and Survival Outcomes

To determine differences in the expression levels of IL15, IL17RA, AGER, MIF, and TNFRSF1A in LUAD and normal tissues, their expression levels were analyzed using the GEPIA (31). As shown in Figure 4, IL15, IL17RA, AGER, and TNFRSF1A were significantly downregulated, whereas MIF was significantly upregulated in LUAD (n = 483) than those in normal tissues (n = 347). Furthermore, TNFRSF1A was significantly downregulated in EGFR-mutant LUAD (n = 85) than that in EGFR wildtype LUAD (n = 394) (P < 0.001). IL17RA was weakly upregulated in EGFR-mutant LUAD than that in EGFR wildtype LUAD, but not reached a significant level (P = 0.078, Figure 5). There was no difference between the expression levels of IL15, AGER, and MIF and EGFR mutation status (P > 0.05).

FIGURE 4

Figure 4 The expression levels of IL15, IL17RA, AGER, MIF, and TNFRSF1A in LUAD in GEPIA. (A), IL15. (B), IL17RA. (C), AGER. (D), MIF. (E), TNFRSF1A. *|Log2FC| > 1.00 and P < 0.010.

FIGURE 5

Figure 5 The expression levels of IL15, IL17RA, AGER, MIF, and TNFRSF1A according to EGFR mutation status. (A), IL15. (B), IL17RA. (C), AGER. (D), MIF. (E), TNFRSF1A.

The effect of IL15, IL17RA, AGER, MIF, and TNFRSF1A expression on survival in LUAD was also analyzed using UCSC Xena. Both low AGER expression and high TNFRSF1A expression were significantly associated with worse PFS in LUAD (P < 0.05, Figure 6). No difference in PFS was observed between low and high IL15, IL17RA, and MIF expression groups (P > 0.05). In addition, low IL17RA and AGER expression, high MIF and TNFRSF1A expression were significantly associated with worse OS in LUAD (P < 0.05, Figure 7). No difference in OS was observed between low and high IL15 expression groups (P = 0.186). Given that the degree of systemic inflammation in elderly patients may influence the response to anticancer treatment (35, 36), we further evaluated the effects of IL15, IL17RA, AGER, MIF, and TNFRSF1A expression on clinical outcome of LUAD patients stratified by age. Low AGER expression was significantly associated with shorter PFS in both patients younger than 75 years and those aged 75 years or older (P < 0.05), whereas high TNFRSF1A expression was only significantly associated with shorter PFS in patients younger than 75 years (P = 0.010, Figure 8). In addition, low AGER expression, high MIF and TNFRSF1A expression were significantly associated with shorter OS only in patients younger than 75 years (P < 0.05, Figure 9).

FIGURE 6

Figure 6 Kaplan-Meier curves of PFS for LUAD patients. (A), IL15. (B), IL17RA. (C), AGER. (D), MIF. (E), TNFRSF1A.

FIGURE 7

Figure 7 Kaplan-Meier curves of OS for LUAD patients. (A), IL15. (B), IL17RA. (C), AGER. (D), MIF. (E), TNFRSF1A.

FIGURE 8

Figure 8 Kaplan-Meier curves of PFS for LUAD patients stratified by age. (A, E), the PFS curves of LUAD patients younger than 75 years were assessed according to IL15, IL17RA, AGER, MIF, and TNFRSF1A expression, respectively. (F–J), the PFS curves of LUAD patients aged 75 years or older were assessed according to IL15, IL17RA, AGER, MIF, and TNFRSF1A expression, respectively.

FIGURE 9

Figure 9 Kaplan-Meier curves of OS for LUAD patients stratified by age. (A–E), the OS curves of LUAD patients younger than 75 years were assessed according to IL15, IL17RA, AGER, MIF, and TNFRSF1A expression, respectively. (F–J), the OS curves of LUAD patients aged 75 years or older were assessed according to IL15, IL17RA, AGER, MIF, and TNFRSF1A expression, respectively.

Discussion

The EGFR mutation rate in NSCLC is relatively high (~50.2%) and thus the EGFR-TKIs are the most commonly used targeted drugs for the treatment of NSCLC (6, 7). Although the PFS and OS of osimertinib are significantly longer than those of the first- and second-generation EGFR-TKIs, the problem of acquired osimertinib resistance still exists in long-term use (8, 12, 37). How to improve or maintain the sensitivity of EGFR-TKIs, delays the onset of resistance, and overcomes acquired resistance to EGFR TKIs in NSCLC patients is still an area with unmet high clinical needs. In the present study, we evaluated the association of SNPs in inflammation genes with the prognosis of advanced NSCLC patients treated with EGFR-TKIs. SNPs in inflammation genes were associated with worse PFS and OS of NSCLC patients. Therefore, SNPs in inflammation genes may be independent prognostic factors for poor prognosis of NSCLC patients treated with EGFR-TKIs.

Inflammation play a critical role in the development and progression of cancer (15, 16). The field of cancer-related inflammation has expanded tremendously over the past decade, and the underlying cellular and molecular mechanisms have been being unraveled one after another. Inflammatory markers may be used as clinically prognostic markers for predicting outcome and monitoring the cancer progression, whereas anti-inflammatory therapy may be a potential regimen for cancer treatment (27, 28, 38, 39). It is estimated that approximately 25% of cancer cases are related to infectious diseases and chronic inflammation (40). The reduction of inflammatory molecule production has been shown to enhance the sensitivity of NSCLC with EGFR mutation to EGFR-TKIs (41). In support of the hypothesis that inflammation is associated with cancer development and progression and also influence the response to treatment, we found that 3 SNPs (rs10519613, rs4819554, and rs4149570) and 5 SNPs (rs10519613, rs4819554, rs2070600, rs755622, and rs4149570) were associated with worse PFS and OS of advanced NSCLC patients treated with EGFR-TKIs, respectively. The effect was increased in NSCLC patients with intermediate and high GRSs, indicating that these patients may have higher levels of systemic inflammation. These findings imply that among patients with intermediate and high GRSs, there is less clinical benefit from EGFR-TKI therapy, as might be expected that this effect is weakened by inflammation. Patients with intermediate and high GRSs seem to be more likely to develop resistance to EGFR-TKIs and may have a high risk of developing EGFR-TKI-induced adverse events such as pneumonitis. SNPs in inflammation genes could discriminate the clinical outcome of NSCLC patients and might affect follow-up and therapeutic strategies after treated with EGFR-TKIs.

A study by Umekawa et al. (20) revealed that EGFR-TKIs may inhibit cancer-related inflammatory response and tumor growth, and improve the prognosis and quality of life of patients. A recent study by Jia et al. (42) found that EGFR-TKIs can modify the tumor microenvironment (TME) during which the levels of cytotoxic CD8⁺ T cells and dendritic cells (DCs) were rapidly elevated, Foxp3⁺ regulatory T cells (Tregs) were eliminated, and M2-like polarization of macrophages was suppressed at an early stage, which were only temporary and disappeared as treatment continued. However, long-term EGFR-TKI treatment leads to the transformation of tumor immunosurveillance into tumor-promoting inflammation through the induction of Tregs, inhibition of DCs, and the polarization of macrophages toward the M2 phenotype (42, 43). MIF is a pro-inflammatory cytokine that functions as a critical molecule in the innate immune system and involves in carcinogenesis, cancer cell proliferation, invasion, metastasis, angiogenesis, and drug resistance, and dampens the anti-tumor immune response (44–49). Our analysis also revealed that high MIF expression was associated with worse prognosis in LUAD cohort. Furthermore, rs755622 were significantly with worse prognosis of NSCLC patients treated with EGFR-TKI. rs755622 in the promoter of MIF affects transcription activity that subsequently results in an increased expression of MIF (50). Therefore, elevated MIF not only suppresses immune surveillance and anti-tumor immune responses and promotes tumor growth, but also favors cancer cell survival against anticancer drugs (46, 47, 49). Inhibition of MIF not only suppresses cancer cell proliferation, but also enhance the sensitivity of cancer cells to anticancer drugs, including EGFR-TKIs, and overcomes anticancer drug resistance (45–48).

Tumor necrosis factor (TNF) is a key regulator of innate immunity and plays a paradoxical and dual role in human cancers, promoting cancer survival or cell death depending on the cellular context (51). The pleiotropic activities of TNF are mediated through two distinct cell surface receptors, TNFRSF1A and TNFRSF1B. Some studies have shown that TNF signaling pathway contributes to the development of drug resistance in NSCLC, breast cancer, and clear cell renal cell carcinoma (52–54). TNF inhibition via TNFRSF1A silencing, etanercept, or thalidomide increases sensitivity of lung cancer cells to EGFR-TKIs, whereas TNF overexpression attenuates apoptosis induction by EGFR-TKIs (54). Although TNFRSF1A was significantly downregulated in TCGA LUAD cohort, high TNFRSF1A expression predicted a worse prognosis. rs4149570 in the promoter of TNFRSF1A affects its expression level (55). Lee et al. (52) reported that rs4149570 was associated with worse prognosis in patients with early-stage NSCLC. In this study, rs4149570 was also associated with worse prognosis in advanced NSCLC patients treated with EGFR-TKI. These pieces of evidence indicate that TNF signaling pathway is extensively implicated in the progression and treatment response in NSCLC.

IL15 is a pleiotropic cytokine best known for its ability to induce T and natural killer (NK) cell activation and proliferation. Combination of IL15 or its superagonists with immune checkpoint inhibitors showed obvious antitumor effects (56). Two studies showed that rs10519613 in IL15 was associated with the risk of minimal residual disease (MRD) in pediatric acute lymphoblastic leukemia (57, 58). Zhang et al. (59) observed that rs10519613 was associated with poor prognosis of HBV-related hepatocellular carcinoma after liver transplantation. In this study, we found that rs10519613 was associated with worse PFS and OS in advanced NSCLC patients treated with EGFR-TKI. The function of rs10519613 is unknown and thus further studies are required to elucidate its function.

IL17 is a T cell-derived proinflammatory cytokine that is essential for a variety of processes such as innate immune defenses, tissue repair, the pathogenesis of autoimmune and inflammatory diseases, and cancer progression (60). IL17RA is one of five IL17 receptors (IL-17RA to IL-17RE) and is widely expressed in a variety of tissues. Two studies reported that the protein level of IL-17RA were significantly increased in NSCLC tissues (61, 62), whereas Liu et al. (63) found no difference in IL-17RA protein expression between NSCLC and normal lung tissues. However, IL17RA was significantly downregulated in TCGA LUAD cohort. This inconsistency may be partly due to tumor heterogeneity and different detection techniques. rs4819554 in the promoter of IL-17RA affects its expression levels and is associated with susceptibilities of some diseases such as autoimmune diseases and cancer (62, 64–66). Furthermore, rs4819554 was significantly associated with the response to anti-TNF drugs in psoriasis patients (67). Given that high expression levels of IL17RA in EGFR-mutated LUAD, NSCLC patients treated with EGFR-TKIs with risk allele seem to have higher expression levels of IL17RA, indicating elevated levels of proinflammatory cytokines in NSCLC tissues (61). This may attribute to the progression of lung cancer and the development of acquired resistances during therapy.

AGER is a multiligand cell surface receptor that involves in initiating of pro-inflammatory intracellular signaling pathways (68). AGER signaling pathway plays an important role in diverse physiological and pathophysiological processes and diseases such as autoimmune diseases and cancer. Previous studies have shown that AGER is downregulated in lung cancer and exhibits tumor suppression function (69–71). Furthermore, knockdown of AGER decreases both the quantity and suppressive activity of tumor-induced myeloid-derived suppressor cells (MDSCs) (72). However, the infiltration of MDSCs is consistently increased throughout the periods of EGFR-TKI treatment, which can inhibit antitumor immune responses, facilitate cancer progression, and lead to EGFR-TKI resistance (42, 73). rs2070600 may promote glycosylation of AGER and affect its splicing (74, 75). Many studies have demonstrated that rs2070600 is associated with many diseases such as autoimmune diseases and lung cancer (68, 71, 76). Yamaguchi et al. (76) found that rs2070600 was related to systemic inflammation and poor prognosis of lung cancer. Therefore, high level of systemic inflammation not only means that NSCLC patients may have more adverse risk factors, but also that NSCLC patients may have worse clinical outcome when treated with EGFR-TKIs.

The inherited genetic information is increasingly being used to predict response to therapy and aid in treatment decisions in clinical practice. However, there are very limited data available that inherited genetic variations can predict clinical outcome after treated with EGFR-TKIs. Given extensive intra-tumor and inter-tumor heterogeneity, it is attractive to use inherited genetic variation to predict response, which could allow for more effective tailored treatment for NSCLC patients. Indeed, our finding that SNPs in inflammation genes may influence the benefits of EGFR-TKIs treatment in NSCLC patients is interesting and deserves further investigation. These polymorphisms may affect the baseline level of systemic inflammation, which could potentially impair the efficacy of EGFR-TKIs and enhance the development of resistance to EGFR-TKIs. In addition, there are some limitations in our study that could not be ignored and suggest caution in the interpretation of the findings. First, the sample size was relatively small, which does not provide us with adequate statistical power to rule out the natural variation existing between individuals. Second, NSCLC patients in our study were all unresectable advanced patients. Therefore, the value of these SNPs in resectable NSCLC patients is required to be evaluated. Third, our results preliminarily revealed that the expression levels of inflammatory genes mainly affected the prognosis of patients younger than 75 years not elderly patients aged 75 years or older. Whether SNPs of inflammation genes play different roles in the elderly patients remains to be further evaluated due to only 6 patients aged 75 years or older in the present study. Fourth, the lack of circulating inflammatory biomarkers (such as CRP and cytokines) data makes it impossible to conduct a comprehensive analysis in conjunction with patients’ baseline inflammatory status. Despite these limitations, this study is one of the very few studies to date exploring the impact of inherited genetic variations on the prognosis of advanced NSCLC patients treated with EGFR-TKIs.

Conclusion

We identified 3 SNPs (rs10519613, rs4819554, and rs4149570) and 5 SNPs (rs10519613, rs4819554, rs2070600, rs755622, and rs4149570) in inflammation genes that were prognostic indicators for PFS and OS of advanced NSCLC treated with EGFR-TKIs, respectively. Although further studies are required to confirm the association and elucidate its underlying molecular mechanism, our findings provided evidence that SNPs in inflammation genes may have the potential to serve as prognostic biomarkers for NSCLC in the clinical setting. Further large-scale studies are necessary to validate the applicability of these SNPs as predictive biomarkers in NSCLC patients.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

Ethics Statement

The studies involving human participants were reviewed and approved by the Ethics Committees of Taizhou Central Hospital. The patients/participants provided their written informed consent to participate in this study.

Author Contributions

XZ, HS, and CH designed the research. TY, ML, HL and HY performed the research. XZ, HSL, ZQ and CH provided the clinical samples. XZ, HS, and CH analyzed and interpreted the data, and wrote the paper. HS revised the final version of the manuscript. All authors approved the final version of the manuscript.

Funding

This study was supported by the Taizhou Science and Technology Agency, China (Grant 162yw02-4).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Acknowledgments

We would like to thank the participating patients for their contributions to this study.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.836117/full#supplementary-material

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, et al. Report of Cancer Epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi (2019) 41(1):19–28. doi: 10.3760/cma.j.issn.0253-3766.2019.01.005

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Zhang X, Chen Q, Chen J, He C, Mao J, Dai Y, et al. Association of Polymorphisms in Translesion Synthesis Genes With Prognosis of Advanced Non-Small-Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. J Surg Oncol (2016) 113(1):17–23. doi: 10.1002/jso.24103

PubMed Abstract | CrossRef Full Text | Google Scholar

4. International Early Lung Cancer Action Program I, Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, et al. Survival of Patients With Stage I Lung Cancer Detected on CT Screening. N Engl J Med (2006) 355(17):1763–71. doi: 10.1056/NEJMoa060476

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol (2016) 11(1):39–51. doi: 10.1016/j.jtho.2015.09.009

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Xu Y, Pan Q, Wang C, He C, Su Z, Guo X, et al. Genetic Polymorphisms in Oxidative Stress-Related Genes are Associated With Clinical Outcome in Patients With Advanced Non-Small Cell Lung Cancer Receiving Tyrosine Kinase Inhibitors. Am J Cancer Res (2014) 4(6):934–42.

PubMed Abstract | Google Scholar

7. Shi Y, Li J, Zhang S, Wang M, Yang S, Li N, et al. Molecular Epidemiology of EGFR Mutations in Asian Patients With Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER Study. PloS One (2015) 10(11):e0143515. doi: 10.1371/journal.pone.0143515

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival With Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med (2020) 382(1):41–50. doi: 10.1056/NEJMoa1913662

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Wu SG, Shih JY. Management of Acquired Resistance to EGFR TKI-Targeted Therapy in Advanced Non-Small Cell Lung Cancer. Mol Cancer (2018) 17(1):38. doi: 10.1186/s12943-018-0777-1

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Imamura F, Inoue T, Kunimasa K, Kubota A, Kuhara H, Tamiya M, et al. Switching From First or Second Generation EGFR-TKI to Osimertinib in EGFR Mutation-Positive NSCLC. Lung Cancer Manag (2020) 9(2):Lmt29. doi: 10.2217/lmt-2020-0005

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr., Wu YL, et al. Lung Cancer: Current Therapies and New Targeted Treatments. Lancet (2017) 389(10066):299–311. doi: 10.1016/s0140-6736(16)30958-8

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med (2018) 378(2):113–25. doi: 10.1056/NEJMoa1713137

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Remon J, Steuer CE, Ramalingam SS, Felip E. Osimertinib and Other Third-Generation EGFR TKI in EGFR-Mutant NSCLC Patients. Ann Oncol (2018) 29(suppl_1):i20–7. doi: 10.1093/annonc/mdx704

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Kashiwabara K, Fujii S, Tsumura S, Sakamoto K, Semba H. Additional Bevacizumab in EGFR-Mutant Lung Adenocarcinoma Patients Who had Oligo-Progression After the Failure of EGFR-TKI: A Single-Institute Retrospective Study. Cancer Treat Res Commun (2020) 22:100163. doi: 10.1016/j.ctarc.2019.100163

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-Related Inflammation. Nature (2008) 454(7203):436–44. doi: 10.1038/nature07205

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. Cell (2010) 140(6):883–99. doi: 10.1016/j.cell.2010.01.025

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Ramos-Nino ME. The Role of Chronic Inflammation in Obesity-Associated Cancers. ISRN Oncol (2013) 2013:697521. doi: 10.1155/2013/697521

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Zaynagetdinov R, Stathopoulos GT, Sherrill TP, Cheng DS, McLoed AG, Ausborn JA, et al. Epithelial Nuclear factor-kappaB Signaling Promotes Lung Carcinogenesis via Recruitment of Regulatory T Lymphocytes. Oncogene (2012) 31(26):3164–76. doi: 10.1038/onc.2011.480

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Vlachostergios PJ, Gioulbasanis I, Kamposioras K, Georgoulias P, Baracos VE, Ghosh S, et al. Baseline Insulin-Like Growth Factor-I Plasma Levels, Systemic Inflammation, Weight Loss and Clinical Outcome in Metastatic Non-Small Cell Lung Cancer Patients. Oncology (2011) 81(2):113–8. doi: 10.1159/000331685

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Umekawa K, Kimura T, Kudoh S, Suzumura T, Oka T, Nagata M, et al. Plasma RANTES, IL-10, and IL-8 Levels in Non-Small-Cell Lung Cancer Patients Treated With EGFR-TKIs. BMC Res Notes (2013) 6:139. doi: 10.1186/1756-0500-6-139

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Ulrich CM, Bigler J, Potter JD. Non-Steroidal Anti-Inflammatory Drugs for Cancer Prevention: Promise, Perils and Pharmacogenetics. Nat Rev Cancer (2006) 6(2):130–40. doi: 10.1038/nrc1801

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Kasymjanova G, MacDonald N, Agulnik JS, Cohen V, Pepe C, Kreisman H, et al. The Predictive Value of Pre-Treatment Inflammatory Markers in Advanced Non-Small-Cell Lung Cancer. Curr Oncol (2010) 17(4):52–8. doi: 10.3747/co.v17i4.567

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Kasahara N, Imai H, Naruse I, Tsukagoshi Y, Kotake M, Sunaga N, et al. Glasgow Prognostic Score Predicts Efficacy and Prognosis in Patients With Advanced Non-Small Cell Lung Cancer Receiving EGFR-TKI Treatment. Thorac Cancer (2020) 11(8):2188–95. doi: 10.1111/1759-7714.13526

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Wang RP, Wang XH, Li ZM, Sun JR. Changes in Serum Inflammatory Factors, Adiponectin, Intestinal Flora and Immunity in Patients With Non-Small Cell Lung Cancer. Eur Rev Med Pharmacol Sci (2020) 24(20):10566–72. doi: 10.26355/eurrev_202010_23412

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Chen YM, Lai CH, Rau KM, Huang CH, Chang HC, Chao TY, et al. Impact of Clinical Parameters and Systemic Inflammatory Status on Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients Readministration With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. BMC Cancer (2016) 16(1):868. doi: 10.1186/s12885-016-2917-6

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Jia Y, Li X, Zhao C, Jiang T, Zhao S, Zhang L, et al. Impact of Serum Vascular Endothelial Growth Factor and Interleukin-6 on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Non-Small-Cell Lung Cancer. Lung Cancer (2018) 125:22–8. doi: 10.1016/j.lungcan.2018.08.025

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Yucel S, Bilgin B. The Prognostic Values of Systemic Immune-Inflammation Index and Derived Neutrophil-Lymphocyte Ratio in EGFR-Mutant Advanced Non-Small Cell Lung Cancer. J Oncol Pharm Pract (2021) 27(1):71–7. doi: 10.1177/1078155220913106

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Yun NK, Rouhani SJ, Bestvina CM, Ritz EM, Gilmore BA, Tarhoni I, et al. Neutrophil-To-Lymphocyte Ratio Is a Predictive Biomarker in Patients With Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated With Tyrosine Kinase Inhibitor (TKI) Therapy. Cancers (Basel) (2021) 13(6):1426. doi: 10.3390/cancers13061426

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Yamaoka T, Arata S, Homma M, Homma T, Kusumoto S, Ando K, et al. Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury. Int J Mol Sci (2019) 20(16):4021. doi: 10.3390/ijms20164021

CrossRef Full Text | Google Scholar

30. Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, et al. Risk of Treatment-Related Toxicities From EGFR Tyrosine Kinase Inhibitors: A Meta-Analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. J Thorac Oncol (2017) 12(4):633–43. doi: 10.1016/j.jtho.2016.11.2236

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses. Nucleic Acids Res (2017) 45(W1):W98–w102. doi: 10.1093/nar/gkx247

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, et al. Visualizing and Interpreting Cancer Genomics Data via the Xena Platform. Nat Biotechnol (2020) 38(6):675–8. doi: 10.1038/s41587-020-0546-8

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients With Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). J Thorac Oncol (2014) 9(2):154–62. doi: 10.1097/jto.0000000000000033

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Arrieta O, Cardona AF, Martín C, Más-López L, Corrales-Rodríguez L, Bramuglia G, et al. Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). J Thorac Oncol (2015) 10(5):838–43. doi: 10.1097/jto.0000000000000481

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Nardone V, Giannicola R, Giannarelli D, Saladino RE, Azzarello D, Romeo C, et al. Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated With a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. Life (Basel) (2021) 11(11):1235. doi: 10.3390/life11111235

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G Jr., Reck M, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Elderly Patients With PD-L1-Positive Advanced Non-Small-Cell Lung Cancer: Pooled Analysis From the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 Studies. Lung Cancer (2019) 135:188–95. doi: 10.1016/j.lungcan.2019.07.004

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance Mechanisms to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. Br J Cancer (2019) 121(9):725–37. doi: 10.1038/s41416-019-0573-8

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Ogura Y, Kataoka N, Kunimatsu Y, Tachibana Y, Sugimoto T, Tani N, et al. Predictors of Survival Among Japanese Patients Receiving First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer. Thorac Cancer (2021) 12(1):97–105. doi: 10.1111/1759-7714.13720

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Hou J, Karin M, Sun B. Targeting Cancer-Promoting Inflammation - Have Anti-Inflammatory Therapies Come of Age? Nat Rev Clin Oncol (2021) 18(5):261–79. doi: 10.1038/s41571-020-00459-9

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Hussain SP, Harris CC. Inflammation and Cancer: An Ancient Link With Novel Potentials. Int J Cancer (2007) 121(11):2373–80. doi: 10.1002/ijc.23173

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Yang Z, Chan KI, Kwok HF, Tam KY. Novel Therapeutic Anti-ADAM17 Antibody A9(B8) Enhances EGFR-TKI-Mediated Anticancer Activity in NSCLC. Transl Oncol (2019) 12(11):1516–24. doi: 10.1016/j.tranon.2019.08.003

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Jia Y, Li X, Jiang T, Zhao S, Zhao C, Zhang L, et al. EGFR-Targeted Therapy Alters the Tumor Microenvironment in EGFR-Driven Lung Tumors: Implications for Combination Therapies. Int J Cancer (2019) 145(5):1432–44. doi: 10.1002/ijc.32191

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Zhou J, Qu Z, Sun F, Han L, Li L, Yan S, et al. Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance Into Tumor-Promoting Inflammation. Cancer Immunol Res (2017) 5(3):257–68. doi: 10.1158/2326-6066.Cir-16-0073

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Calandra T, Froidevaux C, Martin C, Roger T. Macrophage Migration Inhibitory Factor and Host Innate Immune Defenses Against Bacterial Sepsis. J Infect Dis (2003) 187 Suppl 2:S385–90. doi: 10.1086/374752

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Guo Y, Hou J, Luo Y, Wang D. Functional Disruption of Macrophage Migration Inhibitory Factor (MIF) Suppresses Proliferation of Human H460 Lung Cancer Cells by Caspase-Dependent Apoptosis. Cancer Cell Int (2013) 13(1):28. doi: 10.1186/1475-2867-13-28

PubMed Abstract | CrossRef Full Text | Google Scholar

46. Cao F, Xiao Z, Chen S, Zhao C, Chen D, Haisma HJ, et al. HDAC/MIF Dual Inhibitor Inhibits NSCLC Cell Survival and Proliferation by Blocking the AKT Pathway. Bioorg Chem (2021) 117:105396. doi: 10.1016/j.bioorg.2021.105396

PubMed Abstract | CrossRef Full Text | Google Scholar

47. de Azevedo RA, Shoshan E, Whang S, Markel G, Jaiswal AR, Liu A, et al. MIF Inhibition as a Strategy for Overcoming Resistance to Immune Checkpoint Blockade Therapy in Melanoma. Oncoimmunology (2020) 9(1):1846915. doi: 10.1080/2162402x.2020.1846915

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Wang Q, Zhao D, Xian M, Wang Z, Bi E, Su P, et al. MIF as a Biomarker and Therapeutic Target for Overcoming Resistance to Proteasome Inhibitors in Human Myeloma. Blood (2020) 136(22):2557–73. doi: 10.1182/blood.2020005795

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Balogh KN, Templeton DJ, Cross JV. Macrophage Migration Inhibitory Factor Protects Cancer Cells From Immunogenic Cell Death and Impairs Anti-Tumor Immune Responses. PloS One (2018) 13(6):e0197702. doi: 10.1371/journal.pone.0197702

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Donn R, Alourfi Z, De Benedetti F, Meazza C, Zeggini E, Lunt M, et al. Mutation Screening of the Macrophage Migration Inhibitory Factor Gene: Positive Association of a Functional Polymorphism of Macrophage Migration Inhibitory Factor With Juvenile Idiopathic Arthritis. Arthritis Rheum (2002) 46(9):2402–9. doi: 10.1002/art.10492

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Shen J, Xiao Z, Zhao Q, Li M, Wu X, Zhang L, et al. Anti-Cancer Therapy With Tnfα and Ifnγ: A Comprehensive Review. Cell Prolif (2018) 51(4):e12441. doi: 10.1111/cpr.12441

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Lee EB, Jeon HS, Yoo SS, Choi YY, Kang HG, Cho S, et al. Polymorphisms in Apoptosis-Related Genes and Survival of Patients With Early-Stage Non-Small-Cell Lung Cancer. Ann Surg Oncol (2010) 17(10):2608–18. doi: 10.1245/s10434-010-1082-4

PubMed Abstract | CrossRef Full Text | Google Scholar

53. Zhang Z, Lin G, Yan Y, Li X, Hu Y, Wang J, et al. Transmembrane TNF-Alpha Promotes Chemoresistance in Breast Cancer Cells. Oncogene (2018) 37(25):3456–70. doi: 10.1038/s41388-018-0221-4

PubMed Abstract | CrossRef Full Text | Google Scholar

54. Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, et al. TNF-Driven Adaptive Response Mediates Resistance to EGFR Inhibition in Lung Cancer. J Clin Invest (2018) 128(6):2500–18. doi: 10.1172/jci96148

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Sainz J, Salas-Alvarado I, López-Fernández E, Olmedo C, Comino A, García F, et al. TNFR1 mRNA Expression Level and TNFR1 Gene Polymorphisms Are Predictive Markers for Susceptibility to Develop Invasive Pulmonary Aspergillosis. Int J Immunopathol Pharmacol (2010) 23(2):423–36. doi: 10.1177/039463201002300205

PubMed Abstract | CrossRef Full Text | Google Scholar

56. Fiore PF, Di Matteo S, Tumino N, Mariotti FR, Pietra G, Ottonello S, et al. Interleukin-15 and Cancer: Some Solved and Many Unsolved Questions. J Immunother Cancer (2020) 8(2):e001428. doi: 10.1136/jitc-2020-001428

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Dawidowska M, Kosmalska M, Sędek Ł, Szczepankiewicz A, Twardoch M, Sonsala A, et al. Association of Germline Genetic Variants in RFC, IL15 and VDR Genes With Minimal Residual Disease in Pediatric B-Cell Precursor ALL. Sci Rep (2016) 6:29427. doi: 10.1038/srep29427

PubMed Abstract | CrossRef Full Text | Google Scholar

58. Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y, et al. Genome-Wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia. Jama (2009) 301(4):393–403. doi: 10.1001/jama.2009.7

PubMed Abstract | CrossRef Full Text | Google Scholar

59. Zhang T, Liu Y, Peng X, Fan J, Peng Z. Association Between Recipient IL-15 Genetic Variant and the Prognosis of HBV-Related Hepatocellular Carcinoma After Liver Transplantation. Dis Markers (2017) 2017:1754696. doi: 10.1155/2017/1754696

PubMed Abstract | CrossRef Full Text | Google Scholar

60. Li X, Bechara R, Zhao J, McGeachy MJ, Gaffen SL. IL-17 Receptor-Based Signaling and Implications for Disease. Nat Immunol (2019) 20(12):1594–602. doi: 10.1038/s41590-019-0514-y

PubMed Abstract | CrossRef Full Text | Google Scholar

61. Huang Q, Du J, Fan J, Lv Z, Qian X, Zhang X, et al. The Effect of Proinflammatory Cytokines on IL-17RA Expression in NSCLC. Med Oncol (2014) 31(9):144. doi: 10.1007/s12032-014-0144-z

PubMed Abstract | CrossRef Full Text | Google Scholar

62. Li Y, Cao ZY, Sun B, Wang GY, Fu Z, Liu YM, et al. Effects of IL-17A on the Occurrence of Lung Adenocarcinoma. Cancer Biol Ther (2011) 12(7):610–6. doi: 10.4161/cbt.12.7.16302

PubMed Abstract | CrossRef Full Text | Google Scholar

63. Liu L, Ge D, Ma L, Mei J, Liu S, Zhang Q, et al. Interleukin-17 and Prostaglandin E2 are Involved in Formation of an M2 Macrophage-Dominant Microenvironment in Lung Cancer. J Thorac Oncol (2012) 7(7):1091–100. doi: 10.1097/JTO.0b013e3182542752

PubMed Abstract | CrossRef Full Text | Google Scholar

64. Sabry D, Aboraia N, Samir M. A Potential Association Between Psoriasin to Rs4819554 of IL-17RA Gene Polymorphism in Psoriasis Egyptian Patients. Arch Dermatol Res (2020) 312(4):273–81. doi: 10.1007/s00403-019-02011-x

PubMed Abstract | CrossRef Full Text | Google Scholar

65. Nada H, Hassan R, Ibrahim RAE, Abdelsalam OE, Fathy A, Toraih EA, et al. Interleukin 17 Receptor A Haplotype Analysis in Chronic Spontaneous Urticaria: A Preliminary Study. J Cosmet Dermatol (2021) 20(4):1331–42. doi: 10.1111/jocd.13730

PubMed Abstract | CrossRef Full Text | Google Scholar

66. Lee YC, Chung JH, Kim SK, Rhee SY, Chon S, Oh SJ, et al. Association Between Interleukin 17/Interleukin 17 Receptor Gene Polymorphisms and Papillary Thyroid Cancer in Korean Population. Cytokine (2015) 71(2):283–8. doi: 10.1016/j.cyto.2014.11.011

PubMed Abstract | CrossRef Full Text | Google Scholar

67. Batalla A, Coto E, Gómez J, Eirís N, González-Fernández D, Gómez-De Castro C, et al. IL17RA Gene Variants and Anti-TNF Response Among Psoriasis Patients. Pharmacogenom J (2018) 18(1):76–80. doi: 10.1038/tpj.2016.70

CrossRef Full Text | Google Scholar

68. Serveaux-Dancer M, Jabaudon M, Creveaux I, Belville C, Blondonnet R, Gross C, et al. Pathological Implications of Receptor for Advanced Glycation End-Product (AGER) Gene Polymorphism. Dis Markers (2019) 2019:2067353. doi: 10.1155/2019/2067353

PubMed Abstract | CrossRef Full Text | Google Scholar

69. Wang Q, Zhu W, Xiao G, Ding M, Chang J, Liao H. Effect of AGER on the Biological Behavior of Non−Small Cell Lung Cancer H1299 Cells. Mol Med Rep (2020) 22(2):810–8. doi: 10.3892/mmr.2020.11176

PubMed Abstract | CrossRef Full Text | Google Scholar

70. de Bittencourt Pasquali MA, Gelain DP, Zeidán-Chuliá F, Pires AS, Gasparotto J, Terra SR, et al. (Retinol) Downregulates the Receptor for Advanced Glycation Endproducts (RAGE) by Oxidant-Dependent Activation of P38 MAPK and NF-kB in Human Lung Cancer A549 Cells. Cell Signal (2013) 25(4):939–54. doi: 10.1016/j.cellsig.2013.01.013

PubMed Abstract | CrossRef Full Text | Google Scholar

71. Wu S, Mao L, Li Y, Yin Y, Yuan W, Chen Y, et al. RAGE may Act as a Tumour Suppressor to Regulate Lung Cancer Development. Gene (2018) 651:86–93. doi: 10.1016/j.gene.2018.02.009

PubMed Abstract | CrossRef Full Text | Google Scholar

72. Wuren T, Huecksteadt T, Beck E, Warren K, Hoidal J, Ostrand-Rosenberg S, et al. The Receptor for Advanced Glycation Endproducts (RAGE) Decreases Survival of Tumor-Bearing Mice by Enhancing the Generation of Lung Metastasis-Associated Myeloid-Derived Suppressor Cells. Cell Immunol (2021) 365:104379. doi: 10.1016/j.cellimm.2021.104379

PubMed Abstract | CrossRef Full Text | Google Scholar

73. Liu L, Wang C, Li S, Bai H, Wang J. Tumor Immune Microenvironment in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Before and After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment: A Narrative Review. Transl Lung Cancer Res (2021) 10(9):3823–39. doi: 10.21037/tlcr-21-572

PubMed Abstract | CrossRef Full Text | Google Scholar

74. Faiz A, Rathnayake SNH, Ten Hacken NHT, Guryev V, van den Berge M, Pouwels SD. Single-Nucleotide Polymorphism Rs2070600 Regulates AGER Splicing and the Sputum Levels of the COPD Biomarker Soluble Receptor for Advanced Glycation End-Products. ERJ Open Res (2021) 7(2):00947–2020. doi: 10.1183/23120541.00947-2020

PubMed Abstract | CrossRef Full Text | Google Scholar

75. Park SJ, Kleffmann T, Hessian PA. The G82S Polymorphism Promotes Glycosylation of the Receptor for Advanced Glycation End Products (RAGE) at Asparagine 81: Comparison of Wild-Type Rage With the G82S Polymorphic Variant. J Biol Chem (2011) 286(24):21384–92. doi: 10.1074/jbc.M111.241281

PubMed Abstract | CrossRef Full Text | Google Scholar

76. Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, et al. AGER Rs2070600 Polymorphism Elevates Neutrophil-Lymphocyte Ratio and Mortality in Metastatic Lung Adenocarcinoma. Oncotarget (2017) 8(55):94382–92. doi: 10.18632/oncotarget.21764

PubMed Abstract | CrossRef Full Text | Google Scholar